Sculati Wealth Management LLC Invests $675,000 in Amgen Inc. $AMGN

Sculati Wealth Management LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 2,419 shares of the medical research company’s stock, valued at approximately $675,000.

Other large investors have also added to or reduced their stakes in the company. Wealth Preservation Advisors LLC bought a new position in shares of Amgen during the 1st quarter worth approximately $25,000. CBIZ Investment Advisory Services LLC lifted its position in shares of Amgen by 1,214.3% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 85 shares during the period. Legacy Investment Solutions LLC bought a new position in Amgen during the second quarter worth $27,000. Activest Wealth Management grew its holdings in Amgen by 3,433.3% in the first quarter. Activest Wealth Management now owns 106 shares of the medical research company’s stock worth $33,000 after purchasing an additional 103 shares during the period. Finally, Quaker Wealth Management LLC increased its stake in Amgen by 200.0% in the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 240 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 0.2%

NASDAQ AMGN opened at $336.74 on Friday. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. The business has a fifty day simple moving average of $294.91 and a 200 day simple moving average of $290.38. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $345.84. The firm has a market capitalization of $181.33 billion, a P/E ratio of 27.53, a PEG ratio of 2.61 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. During the same quarter in the prior year, the business posted $5.58 EPS. The business’s revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 12th. Stockholders of record on Friday, November 21st will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Friday, November 21st. Amgen’s payout ratio is presently 73.57%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Bank of America increased their price objective on shares of Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a research report on Friday, September 26th. Wells Fargo & Company raised their price objective on Amgen from $280.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Raymond James Financial began coverage on Amgen in a research report on Wednesday, September 3rd. They set a “market perform” rating on the stock. Weiss Ratings upgraded Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Finally, The Goldman Sachs Group decreased their price target on shares of Amgen from $405.00 to $400.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $314.05.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the sale, the senior vice president directly owned 7,209 shares of the company’s stock, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 890 shares of Amgen stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the sale, the senior vice president owned 7,082 shares in the company, valued at $2,381,251.68. This trade represents a 11.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 9,036 shares of company stock valued at $2,992,594 over the last three months. Corporate insiders own 0.76% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.